Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 16/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548285 | 1.00 | BCHE (1.00) | BCHECYP2D6TSHRCYP2C19ACHE | |
| Hydrochloric Acid SCHEMBL30259425 | 0.98 | ACHE (1.00) | BCHECYP2D6TSHRCYP2C19ACHE | |
| Hydrochloric Acid SCHEMBL159034 | 0.98 | ACHE (1.00) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL29362277 | 0.87 | BCHE (0.77) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL7343904 | 0.80 | BCHE (1.00) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL11618902 | 0.78 | BCHE (0.67) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL15557154 | 0.77 | BCHE (0.65) | BCHECYP2D6TSHRCYP2C19ACHE | |
| Hydrochloric Acid SCHEMBL821902 | 0.77 | ACHE (0.64) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL7350072 | 0.74 | BCHE (0.63) | BCHECYP2D6TSHRCYP2C19ACHE | |
| SCHEMBL8428712 | 0.74 | BCHE (1.00) | BCHECYP2D6TSHRCYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9820990-B2 | Methods of treating disorders associated with protein aggregation | The University of Pittsburgh—Of the Commonwealth System of Higher Education (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160361319-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150329822-A1 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | Biocant - Associação De Transferência De Tecnologia (PT) | 2015-11-19 | — | — | US | disclosed |
| EP-2935567-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - Centro de Neurociências E Biologia Molecular - Universidade de Coimbra (PT) | 2015-10-28 | — | — | EP | disclosed |
| US-9072772-B2 | Methods of treating disorders associated with protein aggregation | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014097192-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA MOLECULAR - UNIVERSIDADE DE COIMBRA (PT) | 2014-06-26 | — | — | WO | disclosed |
| US-20140047569-A9 | Methods of Treating Disorders Associated with Protein Aggregation | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-02-13 | — | — | US | disclosed |
| CN-101420922-B | Porous calcium phosphate bone material | ETEX CORP | 2013-10-16 | — | — | CN | disclosed |
| US-20130024953-A1 | Methods of Treating Disorders Associated with Protein Aggregation | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-01-24 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20050277197-A1 | Microparticles with multiple fluorescent signals and methods of using same | LUMINEX CORPORATION | 2005-12-15 | — | — | US | disclosed |
| US-6916661-B2 | Microparticles with multiple fluorescent signals and methods of using same | LUMINEX CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040087032-A1 | Microparticles with multiple fluorescent signals and methods of using same | CHANDLER MARK B (US) | 2004-05-06 | — | — | US | disclosed |
| US-6649414-B1 | Microparticles with multiple fluorescent signals and methods of using same | LUMINEX CORPORATION | 2003-11-18 | — | — | US | disclosed |
| EP-1049807-B1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS | LUMINEX CORP (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1204869-A1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS AND METHODS OF USING SAME | Luminex Corporation (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001091553-A1 | COMPOSITE WAFER FOR CONTROLLED DRUG DELIVERY | DEMEGEN, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6268222-B1 | Microparticles attached to nanoparticles labeled with flourescent dye | LUMINEX CORPORATION | 2001-07-31 | — | — | US | disclosed |
| WO-2001013120-A1 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-1999037814-A9 | MICROPARTICLES WITH MULTIPLE FLUORESCENT SIGNALS | LUMINEX CORP (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361319-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION | HTT, ATIC, API5 | BCHE 106/4885CYP2D6 2596/4885TSHR 2332/4885 |
| US-20140047569-A9 | Methods of Treating Disorders Associated with Protein Aggregation | HTT, ATIC, API5 | BCHE 106/4885CYP2D6 2596/4885TSHR 2332/4885 |
| US-20130024953-A1 | Methods of Treating Disorders Associated with Protein Aggregation | HTT, ATIC, API5 | BCHE 106/4885CYP2D6 2596/4885TSHR 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.